QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS

05 Nov 2026 0 comments

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.

Source: NeurologyLive Published 05 Nov 2026 Imported 05 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment